207 related articles for article (PubMed ID: 27771154)
1. Incretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway.
Barbieri M; Marfella R; Esposito A; Rizzo MR; Angellotti E; Mauro C; Siniscalchi M; Chirico F; Caiazzo P; Furbatto F; Bellis A; D'Onofrio N; Vitiello M; Ferraraccio F; Paolisso G; Balestrieri ML
J Diabetes Complications; 2017 Feb; 31(2):295-303. PubMed ID: 27771154
[TBL] [Abstract][Full Text] [Related]
2. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment.
Balestrieri ML; Rizzo MR; Barbieri M; Paolisso P; D'Onofrio N; Giovane A; Siniscalchi M; Minicucci F; Sardu C; D'Andrea D; Mauro C; Ferraraccio F; Servillo L; Chirico F; Caiazzo P; Paolisso G; Marfella R
Diabetes; 2015 Apr; 64(4):1395-406. PubMed ID: 25325735
[TBL] [Abstract][Full Text] [Related]
3. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
4. Incretin drugs as modulators of atherosclerosis.
Gallego-Colon E; Wojakowski W; Francuz T
Atherosclerosis; 2018 Nov; 278():29-38. PubMed ID: 30248550
[TBL] [Abstract][Full Text] [Related]
5. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.
Lu J; Xiang G; Liu M; Mei W; Xiang L; Dong J
Atherosclerosis; 2015 Dec; 243(2):438-48. PubMed ID: 26520898
[TBL] [Abstract][Full Text] [Related]
6. Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling.
Holmes RM; Yi Z; De Filippis E; Berria R; Shahani S; Sathyanarayana P; Sherman V; Fujiwara K; Meyer C; Christ-Roberts C; Hwang H; Finlayson J; Dong LQ; Mandarino LJ; Bajaj M
Diabetologia; 2011 Aug; 54(8):2122-31. PubMed ID: 21562756
[TBL] [Abstract][Full Text] [Related]
7. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of incretins in diabetes.
Advani A; Bugyei-Twum A; Connelly KA
Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
[TBL] [Abstract][Full Text] [Related]
9. Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events.
Packer M
J Diabetes Complications; 2018 Jun; 32(6):616-617. PubMed ID: 29627373
[No Abstract] [Full Text] [Related]
10. APPL1: role in adiponectin signaling and beyond.
Deepa SS; Dong LQ
Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E22-36. PubMed ID: 18854421
[TBL] [Abstract][Full Text] [Related]
11. Dysfunctional APPL1-Mediated Epigenetic Regulation in Diabetic Vascular Injury.
Du Y; Duan Y; Zhao J; Liu C; Zhang Z; Zhang J; Meng Z; Wang X; Lau WB; Xie D; Lopez BL; Christopher TA; Gao E; Koch WW; Liu H; Liu D; Ma XL; Gu G; Wang Y
Arterioscler Thromb Vasc Biol; 2023 Dec; 43(12):e491-e508. PubMed ID: 37795615
[TBL] [Abstract][Full Text] [Related]
12. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
Cariou B
Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
[TBL] [Abstract][Full Text] [Related]
14. A collagen domain-derived short adiponectin peptide activates APPL1 and AMPK signaling pathways and improves glucose and fatty acid metabolisms.
Sayeed M; Gautam S; Verma DP; Afshan T; Kumari T; Srivastava AK; Ghosh JK
J Biol Chem; 2018 Aug; 293(35):13509-13523. PubMed ID: 29991592
[TBL] [Abstract][Full Text] [Related]
15. The potential for renoprotection with incretin-based drugs.
Tanaka T; Higashijima Y; Wada T; Nangaku M
Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
[TBL] [Abstract][Full Text] [Related]
16. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
17. Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals.
Hirano T; Mori Y
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):80-6. PubMed ID: 27186361
[TBL] [Abstract][Full Text] [Related]
18. Increased vascularization of shoulder regions of carotid atherosclerotic plaques from patients with diabetes.
Olson FJ; Strömberg S; Hjelmgren O; Kjelldahl J; Fagerberg B; Bergström GM
J Vasc Surg; 2011 Nov; 54(5):1324-1331.e5. PubMed ID: 21764240
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
[TBL] [Abstract][Full Text] [Related]
20. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
